公开(公告)号：US09102653B2

公开(公告)日：2015-08-11

申请号：US14322165

申请日：2014-07-02

Applicant: NOVARTIS AG

Inventor： Timothy John Ritchie ,  Andrew James Culshaw ,  Christopher Thomas Brain ,  Edward Karol Dziadulewicz ,  Terance William Hart

IPC: C07D239/91 ,  C07D401/04

CPC classification number: C07D401/04 ,  C07D239/91

Abstract: The present specification relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form.

Abstract translation: 本说明书涉及式（I）的喹唑啉酮化合物的用途，其中R 1，R 2，R 3，R 4，R 5和m如说明书和权利要求中所定义，为游离形式或盐形式， 在可能的情况下，以酸加成盐形式。

公开(公告)号：US11708366B2

公开(公告)日：2023-07-25

申请号：US17400458

申请日：2021-08-12

Applicant: Novartis AG

Inventor： Mallesh Bushaboina ,  Xin Chen ,  Atwood Kim Cheung ,  Andrew James Culshaw ,  Timothy Brian Hurley ,  Nancy Labbe-Giguere ,  Wolfgang Miltz ,  David Orain ,  Tajesh Patel ,  Srinivasan Rajagopalan ,  Till Roehn ,  David Andrew Sandham ,  Gebhard Thoma ,  Ritesh Bhanudasji Tichkule ,  Rudolf Wälchli

IPC: C07D471/10 ,  A61K31/438 ,  A61K45/06 ,  C07D519/00

CPC classification number: C07D471/10 ,  A61K45/06 ,  C07D519/00

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;




wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US12157737B2

公开(公告)日：2024-12-03

申请号：US18319585

申请日：2023-05-18

Applicant: NOVARTIS AG

Inventor： Mallesh Bushaboina ,  Xin Chen ,  Atwood Kim Cheung ,  Andrew James Culshaw ,  Timothy Brian Hurley ,  Nancy Labbe-Giguere ,  Wolfgang Miltz ,  David Orain ,  Tajesh Patel ,  Srinivasan Rajagopalan ,  Till Roehn ,  David Andrew Sandham ,  Gebhard Thoma ,  Ritesh Bhanudasji Tichkule ,  Rudolf Wälchli

IPC: A61K31/438 ,  A61K31/506 ,  A61K45/06 ,  C07D471/10 ,  C07D519/00

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20180243297A1

公开(公告)日：2018-08-30

申请号：US15963535

申请日：2018-04-26

Applicant: Novartis AG

Inventor： Benjamin Richard Bellenie ,  Graham Charles Bloomfield ,  Ian Bruce ,  Andrew James Culshaw ,  Edward Charles Hall ,  Gregory John Hollingworth ,  James Neef ,  Matthew Spendiff ,  Simon James Watson

IPC: A61K31/497 ,  C07D413/14 ,  A61K31/5377 ,  C07D405/04 ,  C07D409/14 ,  C07D417/14 ,  C07D401/14 ,  C07D413/04 ,  C07D409/04 ,  C07D403/14 ,  C07D403/04 ,  C07D401/04 ,  C07D405/14 ,  C07D417/04

CPC classification number: A61K31/497 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.